Here are 1-3 brief analogies for Butterfly Network (BFLY):

• The iPhone of medical imaging
• The Tesla of medical diagnostics

• Butterfly iQ+: A handheld, whole-body ultrasound device powered by a single-probe-on-chip technology for medical imaging.
• Butterfly Enterprise Solutions: Integrated hardware, software, and services designed for healthcare systems to deploy and manage point-of-care ultrasound across their network.
• Cloud-based Software Platform: A companion software platform providing AI-powered imaging tools, cloud archiving, and workflow solutions for their ultrasound devices.

Butterfly Network (BFLY) primarily sells its Butterfly iQ ultrasound devices and associated software/services to other companies and organizations within the healthcare sector, rather than directly to individuals for personal use. The company's major customers and partners typically fall into the following categories:

• Healthcare Systems and Hospitals: Large hospital networks, academic medical centers, and smaller clinics integrate Butterfly iQ into various departments (e.g., emergency medicine, critical care, primary care, obstetrics) for clinical use and training. Examples of significant partners or customers include:
  • Mount Sinai Health System (private healthcare organization)
  • Children's Hospital of Philadelphia (CHOP) (private healthcare organization)
• Emergency Medical Services (EMS) and Air Medical Transport Providers: Organizations that provide pre-hospital care, utilizing the device's portability for rapid assessment in ambulances and air medical flights. An example includes:
  • Air Methods (private company)
• Medical Education and Research Institutions: Universities, medical schools, and research facilities that use the devices for teaching students, training clinicians, and conducting studies. An example of a professional society partnership focused on education includes:
  • American College of Emergency Physicians (ACEP) (professional organization, not a public company)
• Global Health and Aid Organizations: Partners working on health initiatives in underserved regions or developing countries, where the device's affordability and portability are highly beneficial. An example includes:
  • UNICEF (United Nations agency, not a public company)
• International Distributors and Strategic Partners: Companies that facilitate the distribution and adoption of Butterfly's products in specific geographic markets outside the United States. An example includes:
  • Jubilant Bhartia Group (a diversified Indian conglomerate with relevant subsidiaries, primarily private in this context)

As Butterfly Network primarily sells to a diverse range of healthcare institutions and through strategic partnerships rather than relying on a few dominant direct buyers, its customer base is quite diversified across these categories, with numerous individual healthcare systems and clinics making up the broader "customer" landscape.

• Taiwan Semiconductor Manufacturing Company (TSM)

Joseph DeVivo, President, Chief Executive Officer, and Chairman of the Board

Joseph DeVivo currently serves as President, Chief Executive Officer, and Chairman of the Board at Butterfly Network, a position he assumed in April 2023. He possesses 36 years of business leadership experience, with 22 years in the medical device industry and eight years in Digital Health. Before joining Butterfly Network, DeVivo was President of Hospitals and Health Systems at Teladoc Health and CEO and Director at InTouch Health. He also held executive roles at companies such as AngioDynamics, Smith+Nephew, RITA Medical Systems, Computer Motion Inc, and U.S. Surgical. DeVivo has a strong track record of business achievements, including acquiring and integrating eight companies, engineering four complex business turnarounds, and successfully executing three company exits as CEO and two as Chairman. Notably, he was instrumental in the sale of InTouch Health to Teladoc Health for $1.1 billion and the successful sale of Caption Health to GE Healthcare.

John Doherty, Executive Vice President and Chief Financial Officer

John Doherty is set to become Butterfly Network's Executive Vice President and Chief Financial Officer, effective December 8, 2025. He brings over 25 years of global financial leadership experience, guiding both public and private companies through significant growth and strategic transactions. His previous roles include Chief Financial Officer at Kaltura and Chief Financial and Operating Officer at Magic Leap, where he secured over $1 billion in financing and led a comprehensive recapitalization. Doherty also served as Chief Financial Officer of InterXion Holding N.V., where he significantly grew revenue and EBITDA and played a key role in the company's $8 billion combination with Digital Realty Trust. Earlier in his career, he spent 30 years at Verizon Communications, Inc., holding various financial leadership positions, including Senior Vice President of Corporate Development and President & Chief Investment Officer of Verizon Ventures, where he led over $100 billion in strategic transactions and corporate restructurings. His current role as a Partner and Co-Head of the Global Portfolio Operations Group at Goldman Sachs, building on the firm's private and growth equity investing businesses, highlights his extensive experience with private equity-backed companies.

Steve Cashman, Chief Business Officer

Steve Cashman was appointed Chief Business Officer of Butterfly Network, effective September 3, 2024. He is known for his extensive health technology expertise, commercial leadership, and strategic foresight. Prior to joining Butterfly Network, Cashman served as President and Chief Executive Officer of Caption Health, an AI-powered ultrasound platform that was acquired by GE Healthcare. He also held the position of Chief Commercial Officer at InTouch Health. Cashman is an active angel investor and board member in the startup community.

Stacey Pugh, Chief Commercial Officer

Stacey Pugh joined Butterfly Network as Chief Commercial Officer, effective March 15, 2021. She is responsible for overseeing the development and implementation of Butterfly's commercial strategy. With over 18 years of experience in the medical device industry, Pugh has held leadership positions across sales, marketing, medical affairs, and business development at companies such as Medtronic, Covidien, and Kinetic Concepts. Before joining Butterfly, she served as Senior Vice President and President of Medtronic's Neurovascular business.

John Martin, M.D., Chief Medical Officer Emeritus

Dr. John Martin is the Chief Medical Officer Emeritus of Butterfly Network. He is an accomplished executive with over 32 years of experience in the medical device industry, having worked with both public and private companies. Dr. Martin has held senior executive positions at various medical device firms, including Senior Vice President, Europe at KCI, where he managed the European business to achieve high double-digit growth. He completed his residency in general surgery and vascular surgery and is board-certified in vascular surgery, as well as a Fellow of the American College of Surgeons.

1. Uncertain Path to Profitability and Financial Fragility: Butterfly Network continues to experience significant net losses and negative adjusted EBITDA, necessitating a continuous need to raise capital. In 2025, the company projected an adjusted EBITDA loss of $32 million to $35 million. Despite recent capital raises that boosted cash reserves, the company's financial fragility is highlighted by shrinking cash reserves in previous years and the ongoing cash burn, which risks further shareholder dilution.
2. Intense Competition: The company operates in a highly competitive medical imaging market, facing established players such as GE Healthcare, Philips, and Siemens Healthineers. These larger competitors possess extensive hospital distribution networks and long-standing relationships with key decision-makers. Some reports have also indicated that older Butterfly iQ+ devices may underperform competitors in image quality, potentially impacting brand reputation and leading to customer churn.
3. Regulatory and Execution Challenges: Butterfly Network faces regulatory uncertainty, particularly regarding the EU's RoHS Directive review concerning lead exemptions for piezoelectric materials in its devices, with a decision expected in Q2 2026. A negative outcome could disrupt supply chains, especially in international markets. Furthermore, the company faces execution risks related to delays in closing large enterprise deals, which can lead to less predictable revenue, and challenges in scaling its AI initiatives and overall ecosystem. Customer concentration also poses a risk, as disruptions in key partnerships could impede revenue growth.

The addressable markets for Butterfly Network's main products and services are primarily within the point-of-care ultrasound (POCUS) and broader ultrasound devices markets, which are segments of the overall medical imaging market.

• Point-of-Care Ultrasound (POCUS) Market:

  • The global point-of-care ultrasound market was valued at approximately USD 3.97 billion in 2024 and is projected to reach about USD 7.93 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.20% from 2025 to 2034.
  • Another estimate places the global POCUS market at USD 5.44 billion in 2023, with a projection to reach USD 7.36 billion by 2030, at a CAGR of 4.4%.
  • In North America, the POCUS market is estimated to be worth USD 2.3 billion by 2032. The U.S. point-of-care ultrasound market size was exhibited at USD 1.26 billion in 2024 and is projected to be worth around USD 2.51 billion by 2034, growing at a CAGR of 7.23% from 2025 to 2034.

• Ultrasound Devices Market:

  • The global ultrasound devices market size was valued at approximately USD 9.79 billion in 2023 and is anticipated to reach USD 13.07 billion by 2030, growing at a CAGR of 4.24% from 2024 to 2030.
  • Another source indicates the global ultrasound equipment market size was USD 9.63 billion in 2024 and is projected to grow to USD 16.91 billion by 2032, exhibiting a CAGR of 7.3%.
  • North America held a significant share of the global ultrasound market, with one report stating it accounted for the largest revenue share of over 29.75% in 2023.
  • The U.S. ultrasound equipment market size is estimated to be USD 2.82 billion in 2025.

• Medical Imaging Market:

  • The global medical imaging market size was valued at USD 40.33 billion in 2023 and is projected to reach USD 70.19 billion by 2032, growing at a CAGR of 6.4%.
  • North America leads the global medical imaging market, contributing approximately 37% of the total revenue share in 2023. The U.S. imaging services market size reached USD 133.76 billion in 2022 and is expected to hit around USD 216.84 billion by 2032.

Here are 3-5 expected drivers of future revenue growth for Butterfly Network (BFLY) over the next 2-3 years:

1. Continued Adoption and Innovation of Hardware: The strong performance of the recently launched iQ3 ultrasound probe, which significantly increased product revenue due to higher selling prices and increased unit fulfillment, is expected to continue driving growth. Future advancements, such as the upcoming P5.1 chip and the sixth-generation Apollo AI chip, are anticipated to surpass current handheld performance standards, further enhancing the company's technological leadership and product appeal.
2. Global Market Expansion: Butterfly Network is actively expanding its international footprint by launching products in new geographies, including Indonesia, the Netherlands, Belgium, Malawi, and Uganda. This international growth has already contributed significantly to revenue and is a key pillar of the company's long-term strategy.
3. Growth in Software and AI-Powered Solutions: The company is heavily investing in and launching new AI-powered software, such as the Compass AI software and the HeartFocus app, which is the first FDA-cleared Butterfly partner app. Additionally, the expansion of the ScanLab AI training app in medical education and the demonstrated clinical and cost benefits from initiatives like the POCUS CARE trial are expected to drive higher-margin software subscription revenue and enhance the overall value proposition for users.
4. Strategic Partnerships and Enterprise Deals: Butterfly Network's focus on securing large enterprise-wide deals with major health systems and expanding partnerships with medical schools, such as the University of Rochester Medical Center and Kansas City University, is a critical driver for recurring digital revenue. These collaborations facilitate broader adoption of their technology across healthcare infrastructure.
5. Expansion into New Care Settings: The company is exploring and expanding into new care settings, including launching a Butterfly HomeCare pilot with a leading Medicare Advantage provider to improve heart failure outcomes through AI-powered imaging. Furthermore, Butterfly Network is strengthening its presence in the veterinary distribution channel, which has shown improved performance and contributed to revenue growth.

Share Repurchases

• No significant share repurchases were identified for Butterfly Network (BFLY) over the last 3-5 years. Instead, the company has primarily focused on share issuances.

Share Issuance

• In January 2025, Butterfly Network completed a public offering of 24,000,000 shares of Class A common stock at $3.15 per share, raising approximately $75.6 million in gross proceeds.
• The net proceeds from the January 2025 offering are intended to fund the development and commercialization of new and existing products and services, as well as for general corporate purposes.
• In February 2021, Butterfly Network went public through a business combination with Longview Acquisition Corp., resulting in approximately $589 million in gross proceeds.

Inbound Investments

• As part of its business combination with Longview Acquisition Corp. in February 2021, Butterfly Network received $175 million from a Private Investment in Public Equity (PIPE).
• Notable PIPE investors included Eldridge, Fidelity Management & Research Company LLC, Glenview, Ridgeback, Tenet Healthcare Corporation, UPMC Enterprises, and Wellington Management.

Capital Expenditures

• Butterfly Network's capital expenditures averaged $7.406 million for fiscal years ending December 2020 to 2024.
• Capital expenditures peaked at $18.302 million in December 2022 and were $5.783 million in 2023 and $2.694 million in 2024.
• The company's latest twelve-month capital expenditures (as of March 31, 2025) were $1.909 million.